Skip to Content

Medical Reimbursement: The Second Valley of Death for Emerging Medical Device Companies


Emerging life sciences companies know well the first valley of death that is encountered - securing initial investment to translate an early medical device concept to a development stage that is attractive to institutional investors and strategic partners. Many in the life sciences community believe - at their own peril - that once this valley is crossed that the biggest challenge has been conquered. Unfortunately, many companies encounter the second valley of death when they find that their development strategy has focused only on regulatory approval to the neglect of designing for reimbursement acceptance.

Morris, Manning & Martin, LLP together with Georgia Bio and SEMDA will bring together a panel of experts to share their experience on the role of reimbursement strategy for the success of the emerging medical device company.  


More Information/Registration

← Back to All Events